Bard/Collagen's Contigen
This article was originally published in The Gray Sheet
Executive Summary
The injectable collagen treatment for urinary incontinence will be marketed by Bard in kits containing six syringes, at a price of $1,800 per kit. The average patient requires treatment with six syringes; "The Gray Sheet," in a Oct. 4 story on the approval of the device (p. 1), said that Contigen could generate as much as $5,400 per treated patient based on clinical trial results showing that patients achieved continence in one to three treatment sessions, with each session requiring between one and six syringes.